Stem cell transplant after CAR-T for acute leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial combines a special type of stem cell transplant (using half-matched donor cells) with CAR-T therapy and memory T-cell infusions for people with acute leukemia that has not responded to treatment or has come back. The goal is to provide a curative treatment for those who do not have a fully matched donor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute leukemia that is either resistant to treatment or has returned.
- You do not have a fully matched sibling or unrelated donor for a standard transplant.
- After CAR-T therapy, you are in complete remission with no detectable cancer cells in the bone marrow and no leukemia outside the marrow.
- Your liver, kidney, and heart function are within acceptable limits for the procedure.
- You are willing to sign a consent form to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether CAR-T cells made from a healthy donor can help treat B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. It's for adults who cannot use their own cells for CAR-T therapy.
This trial tests giving special immune cells (CAR T cells) after a half-matched stem cell transplant. It's for children and young adults with high-risk leukemia or lymphoma that has come back or not responded to treatment.
This trial tests a combination of your own stem cell transplant and a personalized CAR-T cell therapy called CD19-CAR-T. It is for adults with high-risk acute B-lymphoblastic leukemia whose cancer is in remission after initial chemotherapy, and who are able to receive both treatments safely.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
This trial tests a new type of CAR-T cell therapy that targets two proteins on leukemia cells (called CLL1 and CD33). The goal is to help people with acute myeloid leukemia that has relapsed or not responded to standard treatments.
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.